Price
$32.42+1.76%Social Signal Score
Analyst Ratings
1 analystRevenue
$24.95B+385.98%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dominic William Blakemore
- Sector
- Consumer Cyclical
- Industry
- Restaurants
- Employees
- 590,000
- Beta
- 0.65
- Country
- GB
- Piotroski score
- 7 / 9 (Strong)
- Altman Z-score
- 4.80
Financials
Revenue
$24.95B+386.0%Net Income
$1.07B+649.1%EBITDA
$2.49B+622.5%Free Cash Flow
$1.29B+897.0%EPS (diluted)
$0.63+760.7%Shares Outstanding (diluted)
1.70B-12.7%Operating Expenses
$0.00Cash & Debt
$523.00MReturn of Capital
$744.94MDividend per Share
$0.26Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $46.11B | $1.87B | $1.10 |
| 2024 | $55.05B | $1.84B | $0.81 |
| 2023 | $31.07B | $1.60B | $0.75 |
| 2022 | $25.51B | $1.11B | $0.63 |
| 2021 | $17.91B | $357.00M | $0.20 |
| 2020 | $19.94B | $133.00M | $0.08 |
| 2019 | $24.88B | $1.17B | $0.74 |
| 2018 | $22.87B | $1.16B | $0.73 |
| 2017 | $22.57B | $1.16B | $0.71 |
| 2016 | $19.61B | $992.00M | $0.69 |
| 2015 | $17.59B | $869.00M | $0.55 |
| 2014 | $16.85B | $865.00M | $0.52 |
| 2013 | $17.56B | $429.00M | $0.26 |
| 2012 | $27.28B | $588.77M | $0.35 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from CMPGY's reported EPS growth of 9.2% a year over 13 years.
- EPS in 5 years
- $1.71
- Implied price
- $53.01
- Return from $29.88
- 12.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $26.36 — -11.8% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 21 | 26 | 31 | 36 | 41 |
|---|---|---|---|---|---|
| -0.8% | -5.8% | -1.6% | 1.9% | 5.0% | 7.7% |
| 4.2% | -1.0% | 3.3% | 7.0% | 10.3% | 13.2% |
| 9.2% | 3.7% | 8.3% | 12.2% | 15.6% | 18.6% |
| 14.2% | 8.5% | 13.2% | 17.3% | 20.8% | 24.0% |
| 19.2% | 13.2% | 18.2% | 22.4% | 26.1% | 29.5% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+0.00%Social Signal Score
Mentions (31)
- Newsbusinesswire.com·4d ago·Neutral
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to one senior leader and ten newly hired non-executive employees. The equity awards for the senior lea
View source ↗ - Newsglobenewswire.com·4d ago·Negative
Compass Diversified Declares Third Quarter 2026 Distributions on Series A, B and C Preferred Shares WESTPORT, Conn., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Compass Diversified (NYSE: CODI) (“CODI” or the “Company”), an owner of leading middle market businesses, announced today that its Board of Directors (the “Board”) has declared a quarterly cash distribution for each of its three preferred share series.
View source ↗ - Newsseekingalpha.com·5d ago·Positive
Compass Minerals International Continues To Trade On The Cheap Even After Soaring Compass Minerals International remains a ‘buy' as fundamentals strengthen and shares trade at a compelling valuation. Revenue and profitability improved despite volume declines, driven by higher salt prices and operational discipline. Salt segment pricing power offset lower highway salt volumes, while Plant Nutrition benefited from intentional portfolio adjustments.
View source ↗ - Newsbusinesswire.com·6d ago·Neutral
Compass Pathways Appoints Kelley Boucher as Chief People Officer LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appointment of Kelley Boucher as Chief People Officer, effective today. This appointment strengthens the Compass executive team as the company continues to scale in support of its mission to bring the first classic psyche
View source ↗ - Newsbarrons.com·10d ago·Neutral
Inside The War Between Real Estate's Compass and Zillow How a court case and listing battle is shaping up.
View source ↗ - Newsmarketbeat.com·11d ago·Negative
Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch Compass Pathways NASDAQ: CMPS executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial infrastructure for a potential U.S. launch following FDA approval and federal rescheduling.
View source ↗ - Newsseekingalpha.com·12d ago·Negative
Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity Compass Therapeutics faces a major setback after tovecimig failed to show an overall survival benefit in biliary tract cancer. CMPX plans to pursue a BLA submission for tovecimig despite FDA guidance recommending a new survival-focused trial. Financial runway extends into 2028, but delays or regulatory setbacks could force CMPX to raise capital from a weakened position.
View source ↗ - Newsmarketbeat.com·13d ago·Negative
Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data Compass Pathways NASDAQ: CMPS said it remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter of 2026, following positive Phase III studies of its synthetic psilocybin treatment in treatment-resistant depression, or TRD.
View source ↗ - Newsmarketbeat.com·13d ago·Negative
Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances Compass Pathways NASDAQ: CMPS expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter, with a potential U.S. launch in the first half of 2027, executives said at the Morgan Stanley Global Healthcare Conference.
View source ↗ - Newsbenzinga.com·13d ago·Negative
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug Compass Therapeutics, Inc. (NASDAQ:CMPX) shares are trading lower on Tuesday as the FDA feedback raises new questions about the timing and requirements for its tovecimig program.
View source ↗ - Newsglobenewswire.com·14d ago·Negative
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the U.S. Food and Drug Administration (FDA) recommended that Compass conduct a trial demonstrating a survival benefit before proceeding wit
View source ↗ - Newsmarketbeat.com·14d ago·Negative
Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears Compass Pathways NASDAQ: CMPS said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and continues to target a potential commercial launch for treatment-resistant depression in the first half of 2027.
View source ↗ - Newsbusinesswire.com·20d ago·Positive
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 and will participate in a fireside chat at 1:00
View source ↗ - News247wallst.com·21d ago·Neutral
Coinbase Jumps 6% on Compass Point Upgrade Ahead of Senate CLARITY Act Vote; Strategy Climbs 3%, MARA Slips Coinbase Global (NASDAQ:COIN | COIN Price Prediction) shares are up 6% to $185.
View source ↗ - Newsbusinesswire.com·24d ago·Positive
Strata Mental Health Solutions Awarded U.S. Healthcare Provider Training Grant from Compass Pathways to Develop Provider Training for COMP360 ATLANTA--(BUSINESS WIRE)--Strata Mental Health Solutions, the expert-led training and implementation partner preparing clinical networks to deliver psychedelic treatments, today announced it has been awarded one of the five U.S. HCP training grants awarded by Compass Pathways (Nasdaq: CMPS) to develop U.S. health care provider training programs for COMP360
View source ↗ - News247wallst.com·25d ago·Positive
Compass CEO Says 42% of Homes Took a Price Cut Compass (NYSE:COMP) CEO Robert Reffkin went on CNBC this morning with a striking data point and a buyer-friendly pitch.
View source ↗ - Newsprnewswire.com·26d ago·Positive
Fluence Selected by Compass Pathways to Develop Post-Approval COMP360 Provider Training New certificate program will prepare clinicians to support patients receiving COMP360 psilocybin treatment, if approved by the FDA NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Fluence, a leading provider of professional education in psychedelic therapy, today announced that it has been selected by Compass Pathways plc (Nasdaq: CMPS) as a recipient of its U.S. healthcare provider training grant program.
View source ↗ - Newsbusinesswire.com·26d ago·Positive
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the U.S. grant program recipients to create training programs for healthcare providers (HCPs) that will be involved in the delivery of psychedelic treatments, such
View source ↗ - Newsbusinesswire.com·26d ago·Positive
Compass Pathways to Participate in Investor Conferences the Week of September 14th LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will participate in the following investor conferences the week of September 14th: H.C. Wainwright Annual Global Investment Conference – New York, NY: Fireside chat at 3:30pm ET on Sept
View source ↗ - Newsfxempire.com·26d ago·Positive
Compass Pathways Forecast: Breakout Could Target $22.51–$25.51 CMPS is testing a breakout after positive Phase 3 data, with a close above $15.40 potentially opening the way toward $22.51–$25.51.
View source ↗ - Newsproactiveinvestors.com·26d ago·Positive
Compass Pathways stock rises as 52-week data show lasting depression relief Compass Pathways (NASDAQ:CMPS) climbed 4% on Wednesday after new 52-week data from the company's Phase III study of COMP360, its investigational oral psilocybin treatment for treatment-resistant depression (TRD). The data, from the open-label Part C portion of Study '005, showed sustained efficacy with an infrequent dosing paradigm of two to four times per year.
View source ↗ - Newsbusinesswire.com·27d ago·Positive
Compass Pathways' New 52-Week Topline Open-Label Data from Phase 3 COMP005 Trial Demonstrates Additional Benefit from Another COMP360 Dose in Part C Extending Durability Out to 1 Year LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the topline 52-week results (Part C) from its Phase 3 COMP005 trial of COMP360, a synthetic, proprie
View source ↗ - Newsbusinesswire.com·32d ago·Neutral
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to thirty-one newly hired non-executive employees. The equity awards were granted on September 1, 2026
View source ↗ - Newsbusinesswire.com·34d ago·Positive
Compass Pathways Recognized as a 2026 Fierce 50 Breakthrough Honoree LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways, a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, has been named a 2026 Fierce 50 Breakthrough honoree by Fierce Pharma, Fierce Biotech and Fierce Healthcare. The Fierce 50 recognizes 50 individuals and organizations driving advancements in medicine, fostering innovation and shaping the future of bi
View source ↗ - Newsbusinesswire.com·35d ago·Positive
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026 LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 2026 Cantor Global Healthcare Conference on September 9, 2026 and will participate in a fireside chat at 3:20pm ET and a panel entitled “PSYCH! Accessing T
View source ↗ - Newsmarketwatch.com·40d ago·Neutral
Here's how the private-listing war between Zillow and Compass could cost home buyers and sellers Real-estate giants Compass and Zillow are battling over control of home listings. Consumer advocates and industry experts warn that buyers and sellers could pay a price.
View source ↗ - Newsseekingalpha.com·41d ago·Positive
Compass Pathways: There Are Different Scenarios To Be Considered In Clinical, Regulatory, And Commercialization Compass Pathways plc is rated Strong Buy with a $25–$30 fair value, reflecting a significant upside to current levels. Compass Pathways' COMP360 offers a capacity advantage over Spravato, enabling four times more patients per monitored hour and supporting higher peak sales estimates. Regulatory momentum is strong, but timing risk exists due to DEA rescheduling, which could create inter
View source ↗ - Newsseekingalpha.com·41d ago·Positive
Compass Pathways: Still A Buy, But The Exit Just Got Complicated COMPASS Pathways remains a Buy, but Eli Lilly's acquisition of AtaiBeckley narrows CMPS's long-term strategic options. COMP360's first-mover advantage in treatment-resistant depression is real but fragile, with approval targeted for H1 2027 and launch timelines described as fluid. BPL-003's short-duration sessions may offer superior site economics versus CMPS's 6-hour COMP360 protocol, raising competitive risks.
View source ↗ - Newsmarketbeat.com·54d ago·Negative
Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances Compass Pathways NASDAQ: CMPS said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter of this year, with a potential U.S. launch expected in the first half of 2027.
View source ↗ - Newsmarketbeat.com·56d ago·Neutral
Compass Diversified Q2 Earnings Call Highlights Compass Diversified NYSE: CODI reported second-quarter results marked by double-digit growth in subsidiary adjusted EBITDA, improved operating cash flow and lower debt following the sale of Sterno's food service business, while maintaining its full-year 2026 outlook.
View source ↗ - Newsmarketbeat.com·59d ago·Neutral
Compass Minerals International Q3 Earnings Call Highlights Compass Minerals International NYSE: CMP reported fiscal third-quarter adjusted EBITDA of $39.9 million, compared with $41 million a year earlier, as stronger pricing in its salt and plant nutrition businesses was offset by lower highway de-icing volumes and higher production and distribution costs in salt.
View source ↗
Earnings
Tue, Nov 24(in 7 weeks)
Consensus estimate $0.75 per share
Typical surprise +1.3% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, May 11$0.73 vs $0.71beat
- Tue, Nov 25$0.67 vs $0.67beat
- Wed, May 14$0.65 vs $0.63beat
- Thu, Feb 6$0.60 vs $0.60beat
- Wed, May 15$0.59 vs $0.59beat
- Mon, Nov 20$0.54 vs $0.54miss
Estimates and results for CMPGY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (26d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 8, 2023 (26d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 7, 2023 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 8, 2023 (26d later)Buy$15,001 - $50,000
- Shelley Moore Capitosenate · WV · disclosed Oct 16, 2017 (41d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.